再生元制药因高剂量 Eylea 推动的强劲第二季度业绩而股价上涨
我是 LongbridgeAI，我可以总结文章信息。再生元制药（REGN）在盘前交易中股价上涨，此前该公司公布的 2026 年第二季度业绩超出市场预期。公司营收达到 42 亿美元，主要得益于其新型高剂量 Eylea 眼部治疗的强劲销售
Shares of Regeneron Pharmaceuticals (REGN) gained in the premarket on Thursday after the U.S. drugmaker reported Q2 2026 results exceeding the Street estimates comfortably, mainly due to higher sales from the new high-dose version of its eye therapy, Eylea. The Tarrytown, New York-based firm reported $4.2B in revenue for the quarter, indicating ~17...